This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
ECLIPSE Trial
Oral EPI-7386
SPLASH Trial
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO 2023
AUA 2023
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Renal Cancer
Viewing 1-20 of 68 articles
ASCO GU 2018: The CLEAR study: A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma
ASCO GU 2018: Self-reported Quality of Life as a Predictor of Survival in Renal Cell Carcinoma
ASCO GU 2018: Treatment Facility Volume and Survival in Patients with metastatic Renal Cell Carcinoma
ASCO GU 2018: Carcinomas of the Renal Medulla: A Comprehensive Genomic Profiling Study
ASCO GU 2018: Association of Dividing Pathologically Upstaged T3a Renal Cell Carcinoma with Improved Alignment of Outcomes: A Call for TMN Revision
ASCO GU 2018: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
ASCO GU 2018: Treatment trends of localized renal cell carcinoma by hospital type: A NCDB analysis
ASCO GU 2018: Effects of Patient Gender on Urologist Decision-Making Regarding Treatment of the Localized Renal Mass Introduction and Objective
ASCO GU 2018: Systemic Immune Inflammation Index and Treatment Response in Patients with Metastatic Renal Cell Cancer
ASCO GU 2018: Does Treatment Approach for Small Renal Masses Affect Survival in Patients 70 Years Old?
ASCO GU 2018: Outcomes and Patterns of Disease Progression in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
ASCO GU 2018: The Impact of Facility Case Volume on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in The Targeted Therapy Era
ASCO GU 2018: Impact of Intravenous Acetaminophen on Outcomes following Radical Nephrectomy
ASCO GU 2018: Defining Individual Recurrence Risk Following Surgery for High Risk Non-Metastatic Renal Cell Carcinoma
ASCO GU 2018: Utilization and Survival Implications of a Delayed Approach to Targeted Therapy for Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study
ASCO GU 2018: Imaging Modalities Used for Follow-Up of Localized Renal Cell Carcinoma and Subsequent Effect on Overall Survival after Recurrence: RECUR-Database Analysis
ASCO GU 2018: Title Dose Escalation of Cabozantinib as a Viable Option for the Treatment of mRCC
ASCO GU 2018: S-TRAC trial: Sensitivity Analyses of Disease-Free Survival
ASCO GU 2018: High Dose Interleukin-2 and Response in 944 Patients with Metastatic Renal Cell Cancer (RCC): Data From the PROCLAIM Registry
ASCO GU 2018: Differential Expressions of PD-1, PD-L1, and PD-L2 Between the Primary and Metastatic Sites in Renal Cell Carcinoma
1
2
3
4
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free